RxDoctor Payments Data

Igor Naryzhny, DO

Gastroenterology · Libertyville, ILNPI 1679701239

Payments from drug & device makers

$7,578in general payments, 2019–2025

Across 401 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Gilead$1K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$687
  • QOL Medical, LLC$302
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$7,578100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,578 in reported general payments places this provider in the 75th percentile of 787 gastroenterology providers in Illinois.

See all gastroenterology providers in Illinois

Medicare billing

Part B allowed, 2024
$319,143
Medicare patients
666
Services billed
3,318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide137$106,607
XifaxanRifaximin23$81,831
TrulancePlecanatide21$19,310
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates152$9,837
Budesonide DrBudesonide26$8,875
MotegrityPrucalopride Succinate11$7,698
Budesonide EcBudesonide15$5,889
Mesalamine19$4,749
Ursodiol50$4,442
Pantoprazole Sodium457$3,731
Colestipol Hcl38$2,646
Sucralfate65$1,580
Dicyclomine Hcl48$1,085
Lubiprostone12$1,026
Famotidine75$887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,312$106,607137 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$687$101,14144 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$1,108$7,69811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 787 gastroenterology providers in Illinois.

Other gastroenterology in Libertyville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →